Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06689215
Active, not recruiting Observational

Comparison of Noninvasive vs. Invasive Hemodynamic Measurements

NCT06689215 · tracked via the Priya Life Science USA tracker
Sponsor
Nihon Kohden
Phase
Observational
Started
2024-10-21
Last updated
2026-02-13

Condition(s) studied

Heart Failure, Congestive

Investigational drug(s) / intervention(s)

Non-invasive central venous pressure

Non-invasive central venous pressure: Non-invasive method to measure central venous pressure indicator

Study summary

Comparison of a non-invasive method of measuring central venous pressure to the conventional modality of invasive central venous pressure.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adult age over 18 years. 2. Arm circumference is 18 cm to 55 cm 3. Subject will have an existing indwelling central venous catheter during their ICU stay 4. Subject or legally authorized representative (LAR) is able to understand the risks and potential benefits of participating in the study and is willing to provide written informed consent 5. Subject or LAR is willing and able to comply with protocol procedures Exclusion Criteria: 1. Finger and/or upper arm anatomical anomaly or disease that may interfere with attaching a pulse oximeter sensor and/or blood pressure cuff. 2. Pregnant (self-reported) 3. Upper extremity deep venous thrombosis currently being treated 4. Severe skin disease involving the upper arm(s) 5. Study investigator may exclude patients based on clinical judgement

Primary outcome measure(s)

  • Non-invasive pressure indicator — 1-7 days
    Evaluate sensitivity and specificity of ezCVP indication based on the case where CVP is in a 'low range' (0 \< CVP \< 10 mmHg) or 'high range' (\>= 10 mmHg)

Trial sites (1)

FacilityCityRegionStatus
Stanford University Hospital Stanford California

More Nihon Kohden trials in the USA

Pulse Oximeter Accuracy During Stable Hypoxia Plateaus Active, not recruiting
Determination of SpO2 and PR Accuracy Specifications at Rest (71Ag_Vital-0031) Active, not recruiting
SpO2 Accuracy in Children Enrolling by invitation
Hypoxia and Hemodilution Testing in Healthy Adult Volunteers Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06689215 on ClinicalTrials.gov ↗ ← All trials in the USA